Tyverb still not cost-effective for breast cancer, says NICE
This article was originally published in Scrip
NICE, the UK's National Institute for health and Clinical Excellence, maintains that GlaxoSmithKline's Tyverb (lapatinib) is not cost-effective and should not be used to treat previously treated women with advanced or metastatic breast cancer on the NHS in England and Wales.
You may also be interested in...
Softening provisions to make EU-wide joint clinical assessments voluntary would make proposed legislation on HTA cooperation redundant, says Eurordis.
Plans for EU-wide Joint Clinical assessments will come under scrutiny at an EU council meeting next week.
Pfizer’s Ibrance has won conditional reimbursement in England while more data is gathered to reduce some uncertainty.